Advertisement

Peer Reviewed

Case In Point

Mycoplasma pneumoniae–Induced Rash and Mucositis: 2 Pediatric Cases

Volume 59 - Issue 6 - June 2019

 

    • CASE 2

      A 13-year-old previously healthy girl presented with oral and vulvar mucositis. Five days prior to presentation, she had experienced a sore throat, generalized fatigue, and a temperature as high as 38.3°C. Streptococcal pharyngitis test results were negative. She then developed conjunctivitis and began to have more difficulty swallowing, and she was admitted to the hospital due to dehydration and for intravenous pain control.

      M pneumoniae PCR results were negative at presentation. The patient’s mononuclear spot test results were positive, although more-specific Epstein-Barr virus antibody test results were negative. Despite the negative M pneumoniae PCR results, it was thought that her clinical presentation was most consistent with MIRM. This negative test result may have been due to low levels of M pneumoniae in the nasopharyngeal swab or improper collection or storage of the sample.

      Dermatology, infectious disease, pediatric gynecology, and ophthalmology specialists were consulted during the patient’s admission. She received both intravenous and oral corticosteroids, as well as a 5-day course of azithromycin, after which she showed significant clinical improvement and was discharged home after a 1-week hospitalization.

      DISCUSSION

      Mycoplasma pneumoniae infection classically presents as a respiratory tract infection. However, up to a quarter of patients with Mycoplasma infection experience dermatologic involvement.1 Skin manifestations vary and include erythematous macules, targetoid patches, or vesiculobullous plaques. Severe skin involvement thought to be due to M pneumoniae had previously been classified as a variant Stevens-Johnson syndrome (SJS) or erythema multiforme major.2-4 Recent evidence suggests that mucositis and rash associated with M pneumoniae may be a separate clinical entity altogether.

      NEXT: Clinical Presentation

      CLINICAL PRESENTATION

      MIRM is a newer clinical term that is preferred to older terms such as mycoplasma-induced SJS or mycoplasma-induced erythema multiforme major. The new terminology reflects the causal role of mycoplasma in triggering a clinical picture of severe mucositis with variable and often scant skin involvement.

      MIRM most frequently affects school-aged children or young teenagers. Boys are approximately twice as likely to be affected as girls.5 Prodromal symptoms including low-grade fever, cough, and rhinorrhea are occur approximately 1 week before skin eruption.5

      Skin findings can vary in morphology, with sparse vesiculobullous or targetoid cutaneous lesions being most frequent. Rash is generally less prominent in MIRM compared with SJS.5,6 Mucositis is the predominant clinical finding in these patients, with oral involvement in more than 90% of cases.5 Additional sites of involvement include ocular and urogenital areas.

      Proposed diagnostic criteria include less than 10% of body surface area with skin detachment, 2 or more mucosal sites involved, few vesiculobullous lesions or scattered atypical targetoid lesions, and clinical and laboratory evidence of atypical pneumonia (Table).5

      Table. Comparison of Clinical Findings Differentiating Erythema Multiforme, SJS, and MIRM

       

      Description

      Number of Mucosal Sites Involved

      % Body Involved

      Additional History

      Erythema multiforme major

      Typical target lesions: acrally distributed, <3 cm, round, and well defined with 3 zones of color with 1 edematous ring; atypical target lesions: edematous and round with 2 zones of color and central vesicles or bullae

      Variable

      <10%

      NA

      SJS

      Flat typical target lesions: widespread round, macular with 2 zones of color and potential for central vesicles or bullae; macules with or without blisters: irregular erythematous or purpuric with potential for central vesicles or bullae

      >2

      <10%

      History of medication use

      MIRM

      Sparse vesiculobullous lesions or atypical target lesions; possible typical target lesions

      >2

      <10%

      Clinical or laboratory evidence of atypical pneumonia

      Laboratory evidence of M pneumoniae infection can include immunoglobulin M antibodies, cold agglutinin antibodies, or a positive PCR result.5 Interestingly, the patient described in case 1 had significant esophageal bullae noted on endoscopy. Endoscopy is not frequently carried out for patients with a diagnosis of MIRM; therefore, additional areas of gastrointestinal tract mucosal involvement including esophagitis, gastritis, and perhaps colitis may be an underreported finding in patients with MIRM.7 This hypothesis is supported by the frequent feeding intolerance and need for supplemental enteral or parenteral nutrition in many hospitalized patients with MIRM.3

      Most patients make a full recovery after their acute mucositis has resolved. The milder course and generally good prognosis differentiate MIRM from SJS, which has higher rates of morbidity and mortality. When complications of MIRM do arise, they most frequently include superficial adhesions due to mucosal healing. Pigmentary skin changes may also occur. Although conjunctivitis and dry eye are the most common ocular manifestation, severe ocular complications can occur, including intraocular or extraocular adhesions, which can lead to vision loss if not treated.8 Approximately 8% of patients will experience a recurrence in MIRM symptoms, similar to the patient described in case 1.5 These recurrences are usually associated with a repeated mycoplasma infection.5

      PATHOPHYSIOLOGY

      M pneumoniae primarily infects the respiratory epithelium. The bacterium lacks a cell wall, which allows close contact with the host cells and facilitates transfer of the community-acquired respiratory distress syndrome toxin directly into epithelial cells. This toxin induces the production of proinflammatory cytokines, leading to clinical symptoms of a respiratory tract infection. M pneumoniae has demonstrated ability to localize within the host’s own cells as well as to induce autoantibodies by interacting with the immune system. Proliferation of B cells leading to immune complex deposition in the skin and resulting in activation of the complement cascade has been postulated as being responsible for the skin and mucosal complications of M pneumoniae infections.9,10

      NEXT: Treatment

      TREATMENT

      Patients with MIRM may be treated as an outpatient or admitted to the hospital if mucositis is severe and supportive care for hydration and/or pain management is needed. Additional therapies such as antibiotics, IVIG, oral or intravenous corticosteroids, and immunomodulatory medications can be considered.11-14 Retrospective review shows a trend toward shorter length of stay for patients receiving intravenous corticosteroids either alone or in conjunction with IVIG.15 Small sample size and retrospective data collection make generalization challenging and causation difficult to interpret. It is unclear whether treatment of the underlying M pneumoniae infection changes course of illness, although patients are frequently treated with antibiotics once the diagnosis has been made.16 Observational reports of cyclosporine use in SJS and toxic epidermal necrolysis (TEN) show a propensity toward reduction in symptom duration; however, application of this therapy to the milder MIRM phenotype is of unclear benefit.14 Additional studies are needed to investigate the value of these treatment modalities in MIRM.

      In our experience, patients with MIRM are frequently admitted for severe mucositis leading to dehydration, malnutrition, or inadequate pain control. Admission for observation may be warranted if there is concern for rapid progression of lesions and an alternative diagnosis of SJS or TEN has not been ruled out. In one review, 83% of patients who were admitted with MIRM required parenteral nutrition due to severe mucositis for an average length of 5 days.3 Consultation with a pediatric ophthalmologist and/or a urologist may also be necessary in cases of severe ocular or genitourinary mucosal involvement to avoid vision loss or mucosal adhesions.8 Consultation with a pediatric dermatologist also is useful in establishing the diagnosis and weighing treatment options.

      Supportive care including ocular lubrication, topical and systemic pain control, nutritional support, and hydration are the mainstays of therapy for MIRM. Once patients are stable for outpatient management, pediatric dermatology home follow-up is useful to monitor progression of symptoms. Because MIRM is not related to medication use, patients do not need to avoid any medications in the future.

    References
    1. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev. 2004;17(4):697-728.
    2. Tay Y-K, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol. 1996;35(5 pt 1):757-760.
    3. Prindaville B, Newell BD, Nopper AJ, Horii KA. Mycoplasma pneumoniae–associated mucocutaneous disease in children: dilemmas in classification. Pediatr Dermatol. 2014;31(6):670-675.
    4. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-96.
    5. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae–induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239-24e4.
    6. Bowling M, Schmutzler T, Glick S. Mycoplasma pneumoniae-induced mucositis without rash in an 11-year-old boy. Clin Case Rep. 2018;6(3):551-552.
    7. Norton SA. Diagnosing Mycoplasma pneumoniae-induced rash and mucositis (MIRM) in the emergency room. J Am Acad Dermatol. 2015;73(2):e6
    8. Varghese C, Sharain K, Skalski J, Ramar K. Mycoplasma pneumonia-associated mucositis. BMJ Case Rep. 2014;2014. doi:10.1136/bcr-2014-203795.
    9. Atkinson TP, Waites KB. Mycoplasma pneumoniae infections in childhood. Pediatr Infect Dis J. 2014;33(1):92-94.
    10. Martínez-Pérez M, Imbernón-Moya A, Lobato-Berezo A, Churruca-Grijelmo M. Mycoplasma pneumoniae-induced mucocutaneous rash: a new syndrome distinct from erythema multiforme? Report of a new case and review of the literature. Actas Dermosifiliogr. 2016;107(7):e47-e51.
    11. Santos RP, Silva M, Vieira AP, Brito C. Mycoplasma pneumoniae-induced rash and mucositis: a recently described entity. BMJ Case Rep. 2017;2017. doi:10.1136/bcr-2017-220768.
    12. Demitsu T, Kawase M, Nagashima K, et al. Mycoplasma pneumoniae-associated mucositis with severe blistering stomatitis and pneumonia successfully treated with azithromycin and infusion therapy. J Dermatol. 2019;46(1):e38-e39.
    13. Figueira-Coelho J, Lourenço S, Pires AC, Mendonça P, Malhado JA. Mycoplasma pneumoniae-associated mucositis with minimal skin manifestations. Am J Clin Dermatol. 2008;9(6):399-403.
    14. St. John J, Ratushny V, Liu KJ, et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34(5):540-546.
    15. Ahluwalia J, Wan J, Lee DH, Treat J, Yan AC. Mycoplasma-associated Stevens-Johnson syndrome in children: retrospective review of patients managed with or without intravenous immunoglobulin, systemic corticosteroids, or a combination of therapies. Pediatr Dermatol. 2014;31(6):664-669.
    16. Ravin KA, Rappaport LD, Zuckerbraun NS, Wadowsky RM, Wald ER, Michaels MM. Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series. Pediatrics. 2007;119(4):e1002-e1005.